Savara (SVRA) Other Non-Current Liabilities (2016 - 2025)
Savara's (SVRA) quarterly Other Non-Current Liabilities came in at $44000.0 in Q1 2025, down 78.85% year-on-year from $208000.0 in Q1 2024, and down 49.43% on a QoQ basis from $87000.0 in Q4 2024.
Savara (SVRA) Other Non-Current Liabilities (2016 - 2025) Analysis & Trends
Savara (SVRA) has 10 years of Other Non-Current Liabilities data on file, last reported at $44000.0 in Q1 2025.
- On a quarterly basis, Other Non-Current Liabilities fell 78.85% year-over-year to $44000.0 in Q1 2025; TTM through Mar 2025 was $44000.0, a 78.85% decrease from a year earlier, with the FY2024 full-year figure at $87000.0, down 64.78% from the prior year.
- Other Non-Current Liabilities for Q1 2025 stood at $44000.0, down from $87000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for SVRA reached as high as $284000.0 in Q3 2023 and fell as low as $20000.0 in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $104823.5 across 5 years, with a median of $87000.0 in 2022.
- Across the five-year window, Other Non-Current Liabilities tumbled 99.03% in 2021 and surged 745.0% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $117000.0 in 2021, then tumbled by 53.85% to $54000.0 in 2022, then surged by 357.41% to $247000.0 in 2023, then sank by 64.78% to $87000.0 in 2024, then slumped by 49.43% to $44000.0 in 2025.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $44000.0 in Q1 2025, $87000.0 in Q4 2024, and $128000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 87,000.00 |
| Sep 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Sep 30, 2023 | 284,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 87,000.00 |
| Mar 31, 2022 | 102,000.00 |
| Dec 31, 2021 | 117,000.00 |
| Sep 30, 2021 | 34,000.00 |
| Jun 30, 2021 | 35,000.00 |
| Mar 31, 2021 | 58,000.00 |
| Dec 31, 2020 | 84,000.00 |
| Sep 30, 2020 | 3.10 Mn |
| Jun 30, 2020 | 3.00 Mn |